JP2019513137A - 新規組成物及び治療方法 - Google Patents

新規組成物及び治療方法 Download PDF

Info

Publication number
JP2019513137A
JP2019513137A JP2018549943A JP2018549943A JP2019513137A JP 2019513137 A JP2019513137 A JP 2019513137A JP 2018549943 A JP2018549943 A JP 2018549943A JP 2018549943 A JP2018549943 A JP 2018549943A JP 2019513137 A JP2019513137 A JP 2019513137A
Authority
JP
Japan
Prior art keywords
compound
formula
compounds
composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018549943A
Other languages
English (en)
Japanese (ja)
Inventor
スチスミタ アチャリャ
スチスミタ アチャリャ
サントシュ ケイ． パンダ
サントシュ ケイ． パンダ
プラニャ ダス
プラニャ ダス
ビーモン アガルワル
ビーモン アガルワル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ayuvis Research Inc
Original Assignee
Ayuvis Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ayuvis Research Inc filed Critical Ayuvis Research Inc
Publication of JP2019513137A publication Critical patent/JP2019513137A/ja
Priority to JP2020007053A priority Critical patent/JP7594268B2/ja
Priority to JP2020139289A priority patent/JP7357364B2/ja
Priority to JP2023151493A priority patent/JP7774885B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018549943A 2016-03-30 2017-03-30 新規組成物及び治療方法 Pending JP2019513137A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2020007053A JP7594268B2 (ja) 2016-03-30 2020-01-20 新規組成物及び治療方法
JP2020139289A JP7357364B2 (ja) 2016-03-30 2020-08-20 新規組成物及び治療方法
JP2023151493A JP7774885B2 (ja) 2016-03-30 2023-09-19 新規組成物及び治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662315144P 2016-03-30 2016-03-30
US62/315,144 2016-03-30
PCT/US2017/024908 WO2017173024A1 (en) 2016-03-30 2017-03-30 Novel compositions and therapeutic methods

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020007053A Division JP7594268B2 (ja) 2016-03-30 2020-01-20 新規組成物及び治療方法
JP2020139289A Division JP7357364B2 (ja) 2016-03-30 2020-08-20 新規組成物及び治療方法

Publications (1)

Publication Number Publication Date
JP2019513137A true JP2019513137A (ja) 2019-05-23

Family

ID=59958482

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018549943A Pending JP2019513137A (ja) 2016-03-30 2017-03-30 新規組成物及び治療方法
JP2020007053A Active JP7594268B2 (ja) 2016-03-30 2020-01-20 新規組成物及び治療方法
JP2020139289A Active JP7357364B2 (ja) 2016-03-30 2020-08-20 新規組成物及び治療方法
JP2023151493A Active JP7774885B2 (ja) 2016-03-30 2023-09-19 新規組成物及び治療方法
JP2024000086A Pending JP2024041834A (ja) 2016-03-30 2024-01-04 新規組成物及び治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020007053A Active JP7594268B2 (ja) 2016-03-30 2020-01-20 新規組成物及び治療方法
JP2020139289A Active JP7357364B2 (ja) 2016-03-30 2020-08-20 新規組成物及び治療方法
JP2023151493A Active JP7774885B2 (ja) 2016-03-30 2023-09-19 新規組成物及び治療方法
JP2024000086A Pending JP2024041834A (ja) 2016-03-30 2024-01-04 新規組成物及び治療方法

Country Status (10)

Country Link
US (1) US11207343B2 (https=)
EP (1) EP3436467B1 (https=)
JP (5) JP2019513137A (https=)
KR (2) KR102306956B1 (https=)
CN (2) CN114712383B (https=)
AU (4) AU2017244114B2 (https=)
BR (1) BR112018067833B1 (https=)
CA (2) CA3128743C (https=)
MX (1) MX392849B (https=)
WO (1) WO2017173024A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
JP2019513137A (ja) 2016-03-30 2019-05-23 アユヴィス リサーチ インク．Ａｙｕｖｉｓ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 新規組成物及び治療方法
US20220143059A1 (en) * 2016-03-30 2022-05-12 Ayuvis Research, Inc. Compositions and therapeutic methods
US12594286B2 (en) 2018-07-02 2026-04-07 Ayuvis Research, Inc. Immunodulating small molecules
KR20210027381A (ko) * 2018-07-02 2021-03-10 아유비스 리서치, 인코포레이티드 신규 면역조절 소분자
EP3820512B1 (en) * 2018-07-02 2024-04-24 Ayuvis Research, Inc. Immunomodulating compositions comprising oligosaccharide derivatives
JP7382281B2 (ja) * 2020-05-25 2023-11-16 株式会社東海理化電機製作所 制御装置および制御方法
JP7382280B2 (ja) 2020-05-25 2023-11-16 株式会社東海理化電機製作所 制御装置および制御方法
WO2022169855A1 (en) * 2021-02-04 2022-08-11 Ayuvis Research, Inc. Chitin analogs for the treatment of kidney diseases
US12440471B2 (en) * 2021-07-30 2025-10-14 Ayuvis Research, Inc. Compositions and methods for the treatment of bronchopulmonary dysplasia (BPD) and BPD-associated pulmonary hypertension
WO2023086877A1 (en) * 2021-11-12 2023-05-19 Ayuvis Research, Inc. Novel compositions and therapeutic methods

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4152413A (en) 1978-08-18 1979-05-01 Chromalloy American Corporation Oral vaccine for swine dysentery and method of use
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US4621075A (en) 1984-11-28 1986-11-04 The Procter & Gamble Company Gel-form topical antibiotic compositions
CA1261264A (en) 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
JPH0615476B2 (ja) * 1985-05-22 1994-03-02 イハラケミカル工業株式会社 抗感染症剤
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
FR2640627A1 (fr) * 1988-12-16 1990-06-22 Commissariat Energie Atomique Nouveaux fluorures d'aldosaminyle, leur preparation et leur utilisation pour la fabrication d'oligosaccharides amines lies (1 -> 4)
US5932640A (en) 1989-01-21 1999-08-03 Clariant Finance (Bvi) Limited Dyeability or mass coloration of synthetic polyamide
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
JPH041115A (ja) 1990-04-13 1992-01-06 Pola Chem Ind Inc 皮膚外用剤
EP0570682B1 (en) 1992-05-07 1997-07-23 American Cyanamid Company Synthetic lipid A glycoconjugate antigens for use in vaccines
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
AU7484198A (en) 1997-05-12 1998-12-08 Sage Pharmaceuticals, Inc. Topical spray for burn treatment and anti-infection
US6492350B2 (en) 2000-01-27 2002-12-10 Jdc (Hawaii) Inc. Chitin oligosaccharides and/or chitosan oligosaccharides for preventing or treating common cold or treating pain
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US7098195B2 (en) * 2001-11-28 2006-08-29 Health Research, Inc. Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells
EP1455835A2 (en) * 2001-12-13 2004-09-15 ISM Biopolymer Inc. Method of modulating release of saccharides and uses thereof
AU2003211574A1 (en) * 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US7632654B2 (en) * 2002-04-29 2009-12-15 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Means and methods for detecting endoglycosidase activity
EP1440683A1 (de) 2003-01-23 2004-07-28 Cognis France S.A. Verwendung von Oligoglucosaminen in kosmetischen oder dermatologischen Zubereitungen
CA2428744C (en) 2003-01-24 2013-06-25 University Of Manitoba Inhibition of lysozyme in treating sepsis-induced myocardial dysfunction
US20050255048A1 (en) 2004-05-15 2005-11-17 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
JP5035787B2 (ja) 2005-10-04 2012-09-26 焼津水産化学工業株式会社 α−１、４結合型Ｎ−アセチルグルコサミン含有Ｏ−グリカン型糖鎖の分泌促進剤並びにこれを含有するヘリコバクターピロリ菌を原因とする病態の治療予防剤
FR2892419A1 (fr) * 2005-10-24 2007-04-27 Univ Claude Bernard Lyon I Eta Heteroligomeres de d-glucasamine et n-acetyl-d-glucosamine, leur procede de preparation et leur utilisation
JP5140246B2 (ja) * 2006-03-15 2013-02-06 公益財団法人野口研究所 Ｎ−アセチルグルコサミンの誘導体を含有するピロリ菌増殖抑制剤
GB0622688D0 (en) * 2006-11-14 2006-12-27 Diosamine Dev Corp Novel compounds
ES2543063T3 (es) * 2008-05-16 2015-08-14 Galecto Biotech Ab Nueva síntesis de inhibidores de galactósidos
CN101732338A (zh) 2008-11-26 2010-06-16 中国科学院大连化学物理研究所 壳六糖在制备预防血管生成的药物中的应用
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
CN102475714A (zh) 2010-11-29 2012-05-30 中国科学院大连化学物理研究所 壳寡糖单一化合物在免疫增强药物中的应用
WO2012129802A1 (en) * 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof
EP2885323B1 (en) 2012-08-17 2023-08-30 The University of North Carolina At Chapel Hill Water soluble nitric oxide-releasing polyglucosamines and uses thereof
EP3001838A4 (en) 2013-05-14 2017-02-08 Medlmmune, LLC Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses therof
JP2019513137A (ja) 2016-03-30 2019-05-23 アユヴィス リサーチ インク．Ａｙｕｖｉｓ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 新規組成物及び治療方法
JP7246205B2 (ja) * 2019-02-27 2023-03-27 センクシア株式会社 デッキプレート

Also Published As

Publication number Publication date
EP3436467B1 (en) 2025-08-06
JP7594268B2 (ja) 2024-12-04
EP3436467A4 (en) 2020-03-18
JP7774885B2 (ja) 2025-11-25
CA3015494C (en) 2021-10-26
JP7357364B2 (ja) 2023-10-06
JP2020193215A (ja) 2020-12-03
AU2017244114B2 (en) 2021-07-22
MX2018009802A (es) 2018-12-06
AU2017244114A1 (en) 2018-11-08
KR20210122865A (ko) 2021-10-12
MX392849B (es) 2025-03-24
JP2020090675A (ja) 2020-06-11
CN108884121A (zh) 2018-11-23
AU2023222844A1 (en) 2023-09-14
KR20180125583A (ko) 2018-11-23
AU2021232715A1 (en) 2021-10-14
BR112018067833A2 (pt) 2019-03-19
CA3015494A1 (en) 2017-10-05
US11207343B2 (en) 2021-12-28
JP2023179505A (ja) 2023-12-19
US20170281667A1 (en) 2017-10-05
EP3436467C0 (en) 2025-08-06
CA3128743A1 (en) 2017-10-05
CN108884121B (zh) 2022-05-31
BR112018067833B1 (pt) 2024-03-05
AU2025205307A1 (en) 2025-07-31
CN114712383A (zh) 2022-07-08
CA3128743C (en) 2024-06-25
CN114712383B (zh) 2024-09-24
KR102532825B1 (ko) 2023-05-17
EP3436467A1 (en) 2019-02-06
JP2024041834A (ja) 2024-03-27
KR102306956B1 (ko) 2021-10-01
WO2017173024A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
JP7774885B2 (ja) 新規組成物及び治療方法
KR101367479B1 (ko) 귀 질병 치료를 위한 제어 방출형 항미생물성 조성물 및 방법
KR101390607B1 (ko) 귀 질환 치료를 위한 제어 방출형 아폽토시스 조절 조성물 및 방법
CN105682655A (zh) 抗微生物化合物
KR20170030093A (ko) 결막하 및 눈주위 주사를 위한 사이클로스포린 a의 현탁액 조성물
JP2020512971A (ja) インサイチュゲル形成医薬組成物および副鼻腔疾患のためのその使用
UA126941C2 (uk) Фармацевтичні композиції для інгібування запальних цитокінів
Yuan et al. Extracellular vesicles enhance the efficacy of ceftiofur against intracellular bacterial infections
JP2021535170A (ja) 薬物送達のための相乗的な透過促進剤を伴う組成物
CN113473992A (zh) 用于治疗和预防中性粒细胞胞外陷阱相关并发症的化合物
CN117100862A (zh) Mif和ripk1在围术期缺血性脑损伤中的应用
HK40004181B (en) Beta-anomer-saccharides for use in the treatment of sepsis, septic shock, septicemia, burn or wound infection
HK40004181A (en) Beta-anomer-saccharides for use in the treatment of sepsis, septic shock, septicemia, burn or wound infection
WO2022071233A1 (ja) 優れた保存効力を示す液状医薬組成物
US20220143059A1 (en) Compositions and therapeutic methods
AU2022383860A1 (en) Novel compositions and therapeutic methods
KR20230131694A (ko) 우루소디옥시콜릭산과 프로타민을 포함하는 이상지질혈증 또는 지방간 예방 또는 치료용 조성물
CN118791572A (zh) 一种免疫调节正电抗炎肽及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201012